Last reviewed · How we verify
Pf-07817883 (pf-07817883)
Pfizer's PF-07817883, also known as ibuzatrelvir, is a second-generation oral SARS-CoV-2 main protease inhibitor. It is designed to improve upon the limitations of nirmatrelvir, the active antiviral component of Paxlovid. The drug is currently in the marketed phase and has generated $21.2B in revenue. It is being developed for the treatment of COVID-19. PF-07817883 is a small molecule drug. Its mechanism of action involves inhibiting the SARS-CoV-2 main protease. The drug has shown promise in clinical trials, with 9 trials conducted and 4 publications. It is a best-in-class drug in its class.
At a glance
| Generic name | pf-07817883 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Indication not found
- Indication not found
Common side effects
- Headache
- Constipation
- COVID-19
- Lipase increased
- Muscle spasms
- Vessel puncture site bruise
- Abdominal distension
- Diarrhoea
- Alanine aminotransferase increased
- Diarrhea
- Flatulence
- Nasopharyngitis
Drug interactions
- Warfarin
- Aspirin
- Pentobarbital
- Phenobarbital
- Rivaroxaban
- Apixaban
- Dabigatran
- Clopidogrel
- Ticagrelor
- Prasugrel
- Cilostazol
- Dipyridamole
Key clinical trials
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease (PHASE3)
- A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults (PHASE1)
- A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883. (PHASE1)
- A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults (PHASE1)
- A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers (PHASE1)
- A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People (PHASE1)
- A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized (PHASE2)
- A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-07817883 CI brief — competitive landscape report
- Pf-07817883 updates RSS · CI watch RSS
- Pfizer portfolio CI